Drug resistance and influencing factors of biofilm bacteria in upper urinary calculi patients with double J stent indwelling.


Journal

BMC urology
ISSN: 1471-2490
Titre abrégé: BMC Urol
Pays: England
ID NLM: 100968571

Informations de publication

Date de publication:
14 Oct 2023
Historique:
received: 16 01 2023
accepted: 10 10 2023
medline: 23 10 2023
pubmed: 15 10 2023
entrez: 14 10 2023
Statut: epublish

Résumé

To analyze the distribution and drug resistance of biofilm bacteria infected with upper urinary calculi patients with double J stent indwelling, and to explore the influencing factors of Biofilm Bacteria Infections. A total of 400 patients with upper urinary calculi who adopted double J stent inserting in our hospital from January 2019 to January 2022 were included. Urine and double J stent samples were collected, pathogen cultures were performed, and then drug sensitivity test analysis was carried out for isolates. Univariate and multivariate logistic regression analyzes were used to analyze the influencing factors of patients with double J stent associated biofilm bacteria infections. A total of 13 strains (3.2%) of biofilm bacteria were detected in urine samples and 168 strains (42%) in double J stent samples (P < 0.05), 95 strains (23.7%) of pathogenic bacteria were separated from urine samples and 117 strains (29.2%) from double J-stent samples (P > 0.05). Escherichia coli were the most common bacteria. There was significantly higher drug resistance observed in biofilm bacteria versus urine-cultured pathogens (P < 0.05). Advanced age, long-term catheterization, inadequate water intake, hypoproteinemia, abnormal renal function, and diabetes mellitus were independent risk factors for biofilm bacteria infection associated with double J stent(P < 0.05). Among the upper urinary calculi patients with double J stent indwelling, the positive rate and drug resistance of biofilm bacteria obtained from double J stent were significantly higher than that from urine. More attention should be paid to the factors that influence biofilm bacteria infections.

Identifiants

pubmed: 37838674
doi: 10.1186/s12894-023-01339-x
pii: 10.1186/s12894-023-01339-x
pmc: PMC10576326
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

165

Informations de copyright

© 2023. BioMed Central Ltd., part of Springer Nature.

Références

J Endourol. 2013 Mar;27(3):333-7
pubmed: 22970837
Acta Biomater. 2017 Dec;64:200-210
pubmed: 29024820
Urol Int. 2018;101(3):320-326
pubmed: 30212821
BJU Int. 2017 Jul;120(1):109-116
pubmed: 28236332
Biochim Biophys Acta Rev Cancer. 2019 Aug;1872(1):74-79
pubmed: 31201828
Front Cell Infect Microbiol. 2012 May 08;2:62
pubmed: 22919653
Eur J Clin Microbiol Infect Dis. 2015 May;34(5):877-86
pubmed: 25630538
Infect Immun. 1992 May;60(5):2048-57
pubmed: 1314224
Antimicrob Agents Chemother. 2013 Jan;57(1):196-204
pubmed: 23089750
Science. 2012 Jul 13;337(6091):236-9
pubmed: 22798614
J Endourol. 1995 Dec;9(6):469-72
pubmed: 8775077
Roum Arch Microbiol Immunol. 2010 Oct-Dec;69(4):213-23
pubmed: 21462836
Turk J Med Sci. 2018 Feb 23;48(1):162-167
pubmed: 29479978
World J Urol. 2017 Sep;35(9):1301-1320
pubmed: 28213860
FEMS Microbiol Ecol. 2017 Mar 1;93(3):
pubmed: 28158402
Science. 1999 May 21;284(5418):1318-22
pubmed: 10334980
Urol Res. 2011 Apr;39(2):81-8
pubmed: 20686759
Nat Rev Urol. 2015 Jan;12(1):17-25
pubmed: 25534997
World J Microbiol Biotechnol. 2014 Dec;30(12):3015-25
pubmed: 25298216
Infez Med. 2013 Dec;21(4):287-95
pubmed: 24335459

Auteurs

Qian Chen (Q)

Department of Nephrology, First People's Hospital of Zigong City, Zigong, China.

JunBing Ye (J)

Department of Urology, First People's Hospital of Zigong City, Zigong, China. 295153751@qq.com.

Xiao Bin Li (XB)

Department of Urology, First People's Hospital of Zigong City, Zigong, China.

Ke Zeng (K)

Department of Urology, First People's Hospital of Zigong City, Zigong, China.

Shiping Zeng (S)

Department of Urology, First People's Hospital of Zigong City, Zigong, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH